Treatment of Comorbid Migraine and Temporomandibular Disorders: A Factorial, Double-Blind, Randomized, Placebo-Controlled Study

Aims: To investigate the effectiveness of single and concomitant treatment of migraine and temporomandibular disorders (TMD) in women with the comorbidity. Methods: Eligible female patients met International Classification of Headache Disorders, second edition (ICHD-2) criteria for migraine with or without aura and the Research Diagnostic Criteria for myofascial TMD (Grade ll or lll). After a run-in period (30 days), women with both migraine and TMD were enrolled into a four-arm, double-blind, placebo-controlled, factorial study testing the separate and joint effects of a migraine treatment (propranolol 90 mg) and a TMD treatment (stabilization splint [SS]) in four groups of patients. The four treatment groups were propranolol and SS (n = 22); propranolol placebo and SS (n = 23); propranolol and non-occlusal splint (NOS) (n = 23); and propranolol placebo and NOS (n = 21). The primary endpoint for migraine was change in headache days from baseline to the third month, and the secondary endpoint was change in days with at least moderate headache in the same period. The TMD endpoints included pain threshold and mandibular vertical range of motion. Data were analyzed using analysis of variance (ANOVA, Dunn's post-hoc test) or Kruskal-Wallis test. Results: For the primary endpoint, in intention-to-treat (ITT) analyses (n = 94), propranolol and SS were associated with a nonsignificant reduction in the number of headache days, relative to all other groups. For per-protocol (PP) Completer analyses (n = 89), differences in the number of headache days reached significance (P < .05). The propranolol and SS group was significantly superior to the other groups on all other headache endpoints and in disability, in both ITT and PP analyses. No significant differences among groups were seen for the TMD parameters. Conclusion: In women with TMD and migraine, migraine significantly improved only when both conditions were treated. The best treatment choice for TMD pain in women with migraine is yet to be defined.

clinical trial; migraine; occlusal splint; propranolol; temporomandibular disorders

1. Stewart Wf, Lipton rB, celentano DD, reed ML. Prevalence of migraine headache in the United States. relation to age, income, race, and other sociodemographic factors. JaMa 1992;267:64–69.

2. Lipton rB, Bigal ME, Diamond M, freitag f, reed ML, Stewart Wf. Migraine prevalence, disease burden, and the need for preventive therapy. neurology 2007;68:343–349.

3. Stovner L, Hagen K, Jensen r, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. cephalalgia 2007;27:193–210.

4. Gonçalves DaDG, Dal fabbro aL, campos JaDB, Bigal ME, Speciali JG. Symptoms of temporomandibular disorders in the population: an epidemiological study. J Orofac Pain 2010;24:270–278.

5. american academy of Orofacial Pain. Orofacial Pain: Guidelines for assessment, Diagnosis, and Management, ed

4. de Leeuw r (ed). chicago: Quintessence, 2008:316.

6. Watts PG, Peet KM, Juniper rP. Migraine and the temporomandibular joint: The final answer? Br Dent J 1986; 161:170–173.

7. Dworkin Sf,Leresche L.researchdiagnosticcriteriafortem-poromandibular disorders: review, criteria, examinations and specifications, critique. J craniomandib Disord 1992; 6:301–355.

8. Burstein r, Yarnitsky D, Goor-aryeh i, ransil BJ, Bajwa ZH. an association between migraine and cutaneous allodynia. ann neurol 2000;47:614–624.

9. Bertoli fM de P, antoniuk Sa, Bruck i, Xavier GrP, rodrigues DcB, Losso EM. Evaluation of the signs and symptoms of temporomandibular disorders in children with headaches. arq neuropsiquiatr 2007;65:251–255.

10. Bigal ME, ashina S, Burstein r, et al. Prevalence and characteristics of allodynia in headache sufferers: a population study. neurology 2008;70:1525–1533.

11. Bevilaqua-Grossi D, Lipton rB, napchan U, Grosberg B, ashina S, Bigal ME. Temporomandibular disorders and cutaneous allodynia are associated in individuals with migraine. cephalalgia 2010;30:425–432.

12. Gonçalves Da, Speciali JG, Jales Lcf, camparis cM, Bigal ME. Temporomandibular symptoms, migraine and chronic daily headaches in the population. neurology 2009;73: 645–646.

13. Gonçalves DaG, Bigal ME, Jales Lcf, camparis cM, Speciali JG. Headache and symptoms of temporomandibular disorder: an epidemiological study. Headache 2010; 50:231–241.

14. Stuginski-Barbosa J, Macedo Hr, Bigal ME, Speciali JG. Signs of temporomandibular disorders in migraine patients: a prospective, controlled study. clin J Pain 2010;26: 418–421.

15. Plesh O, noonan c, Buchwald DS, Goldberg J, afari n. Temporomandibular disorder-type pain and migraine headache in women: a preliminary twin study. J Orofac Pain 2012;26:91–98.

16. Gonçalves DaG, camparis cM, Speciali JG, franco aL, castanharo SM, Bigal ME. Temporomandibular disorders are differentially associated with headache diagnoses: a controlled study. clin J Pain 2011;27:611–615.

17. franco aL, Gonçalves DaG, castanharo SM, Speciali JG, Bigal ME, camparis cM. Migraine is the most prevalent primary headache in individuals with temporomandibular disorders. J Orofac Pain 2010;24:287–292.

18. Magnusson T, carlsson GE. recurrent headaches in relation to temporomandibular joint pain-dysfunction. acta Odontol Scand 1978;36:333–338.

19. ramadan nM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: Proof of efficacy, utilization and cost. cephalalgia 1997;17:73–80.

20. Light Kc, Bragdon EE, Grewen KM, Brownley Ka, Girdler SS, Maixner W. adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder. J Pain 2009;10:542–552.

21. nackley aG, Tan KS, fecho K, flood P, Diatchenko L, Maixner W. catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain 2007;128:199–208.

22. Tchivileva iE, Lim Pf, Smith SB, et al. Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenet Genomics 2010;20:239–248.

23. Ekberg Ec, Vallon D, nilner M. Occlusal appliance thera- py in patients with temporomandibular disorders. a double-blind controlled study in a short-term perspective. acta Odontol Scand 1998;56:122–128.

24. franco L, rompre PH, De Grandmont P, abe S, Lavigne GJ. a mandibular advancement appliance reduces pain and rhythmic masticatory muscle activity in patients with morning headache. J Orofac Pain 2011;25:240–249.

25. Quayle aa, Gray rJ, Metcalfe rJ, Guthrie E, Wastell D. Soft occlusal splint therapy in the treatment of migraine and other headaches. J Dent 1990;18:123–129.

26. Shankland WE. nociceptive trigeminal inhibition--tension suppression system: a method of preventing migraine and tension headaches. compend contin Educ Dent 2001;22:1075–1080,1082. corrected and republished in: compend contin Educ Dent 2002;23:105–108,110,112–3.

27. The international classification of Headache Disorders, ed 2. cephalalgia 2004;24(suppl 1):9–160.

28. De Lucena LBS, Kosminsky M, Da costa LJ, De Góes PSa. Validation of the Portuguese version of the rDc/TMD axis ii questionnaire. Braz Oral res 2006;20:312–317.

29. Pereira Junior f, Huggins KH, Dworkin Sf. critérios de Diagnóstico para Pesquisa das Desordens Temporoman- dibulares rDc/DTM—Portuguese Translation [internet]. available from: http://www.rdc-tmdinternational.org

30. cimino r, farella M, Michelotti a, Pugliese r, Martina r. Does the ovarian cycle influence the pressure-pain threshold of the masticatory muscles in symptom-free women? J Orofac Pain 2000;14:105–111.

31. Vignolo V, Vedolin GM, De araujo cDrP, rodrigues conti Pc. influence of the menstrual cycle on the pressure pain threshold of masticatory muscles in patients with masticatory myofascial pain. Oral Surg Oral Med Oral Pathol Oral radiol Endod 2008;105:308–315.

32. Lipton rB, Stewart Wf. The Migraine Disability assessment Test. available from: http://uhs.berkeley.edu/home/health- topics/pdf/assessment.pdf [accessed 30 august 2013].

33. fragoso YD. MiDaS (Migraine Disability assessment): a valuable tool for work-site identification of migraine in workers in Brazil. Sao Paulo Med J 2002;120:118–121.

34. ash MM, ramfjord S. an introduction to functional occlusion. Philadelphia: Saunders, 1982.

35. Silberstein SD, freitag fG. Preventive treatment of migraine. neurology 2003;60(suppl 2):S38–S44.

36. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the american academy of neurology. neurology 2000;55:754–762.

37. Tfelt-Hansen P, rolan P. Beta-adrenoceptor blocking drugs in migraine prophylaxis. in: Olesen J, Goadsby PJ, ramadan nM, Tfelt-Hansen P, Welch KMa (eds). The Headaches, ed 3. Philadelphia: Lippincott Williams & Wilkins, 2006:1200.

38. Bevilaqua Grossi D, Lipton rB, Bigal ME. Temporomandibular disorders and migraine chronification. curr Pain Headache rep 2009;13:314–318.

39. Mørch cD, Hu JW, arendt-nielsen L, Sessle BJ. convergence of cutaneous, musculoskeletal, dural and visceral afferents onto nociceptive neurons in the first cervical dorsal horn. Eur J neurosci 2007;26:142–154.

40. Sessle BJ. neural mechanisms and pathways in craniofacial pain. can J neurol Sci 1999;26(suppl 3):S7–S11.

41. Olesen J. clinical and pathophysiological observations in migraine and tension-type headache explained by integration of vascular, supraspinal and myofascial inputs. Pain 1991; 46:125–132.

42. Maixner W, fillingim r, Sigurdsson a, Kincaid S, Silva S. Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain: Evidence for altered temporal summation of pain. Pain 1998;76:71–81.

43. ayesh EE, Jensen TS, Svensson P. Hypersensitivity to mechanical and intra-articular electrical stimuli in persons with painful temporomandibular joints. J Dent res 2007; 86:1187–1192.

44. Svensson P. Muscle pain in the head: Overlap between temporomandibular disorders and tension-type headaches. curr Opin neurol 2007;20:320–325.

45. Sarlani E, Greenspan JD. Why look in the brain for answers to temporomandibular disorder pain? cells Tissues Organs 2005;180:69–75.

46. Millan MJ. Descending control of pain. Prog neurobiol 2002;66(6):355–474.

47. Ji rr, Kohno T, Moore Ka, Woolf cJ. central sensitization and LTP: Do pain and memory share similar mechanisms? Trends neurosci 2003;26:696–705.

48. Welch KM, Barkley GL, Tepley n, ramadan nM. central neurogenic mechanisms of migraine. neurology 1993;43 (6 Suppl 3):S21–S25.

49. shields K, Goadsby PJ. Propranolol modulates trigemino- vascular response in thalamic ventroposteromedial nucleus: a role in migraine? Brain 2005;128:86–97.

50. Haerter K, ayata c, Moskowitz Ma. cortical spreading depression: a model for understanding migraine biology and future drug targets. Headache currents 2005;2:97–103.

51. Türp Jc, Komine f, Hugger a. Efficacy of stabilization splints for the management of patients with masticatory muscle pain: a qualitative systematic review. clin Oral investig 2004;8:179–195.

52. Speciali JG, Peres M, Bigal ME. Migraine treatment and placebo effect. Expert rev neurother 2010;10:413–419.

53. Kaptchuk TJ, Stason WB, Davis rB, et al. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ 2006;332:391–397.

54. Diener Hc, Schorn cf, Bingel U, Dodick DW. The importance of placebo in headache research. cephalalgia 2008;28:1003–1011.

55. de craen aJ, Tijssen JG, de Gans J, Kleijnen J. Placebo effect in the acute treatment of migraine: Subcutaneous placebos are better than oral placebos. J neurol 2000;247:183–188.

56. Saxena Pr, Tfelt-Hansen P. Triptans, 5-HT 1B/1D receptor agonists in the acute treatments of migraines. in: Olesen J, Goadsby PJ, ramadan nM, Tfelt-Hansen P, Welch KMa (eds). The Headaches, ed 3. Philadelphia: Lippincott Williams & Wilkins, 2006:469–503.

57. rubinoff MS, Gross a, Mccall WD. conventional and nonoccluding splint therapy compared for patients with myofascial pain dysfunction syndrome. Gen Dent 1987;35:502–506.

58. al-ani Z, Gray rJ, Davies SJ, Sloan P, Glenny a. Stabilization splint therapy for the treatment of temporomandibular myofascial pain: a systematic review. J Dent Educ 2005; 69:1242–1250.

59. conti Pcr, de alencar En, da Mota corrêa aS, Lauris Jr, Porporatti a L, costa YM. Behavioural changes and occlusal splints are effective in the management of masticatory myofascial pain: a short-term evaluation. J Oral rehabil 2012; 39:754–760.

60. Stohler cS, Zarb Ga. On the management of temporomandibular disorders: a plea for a low-tech, high-prudence therapeutic approach. J Orofac Pain 1999;13:255–261.

61. Greene cS. Managing the care of patients with temporomandibular disorders: a new Guideline for care. J am Dent assoc 2010;141:1086–1088.